BC Innovations | Jun 20, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture studies suggest inhibiting VCIP135 could help treat botulism. An siRNA screen in an HEK cell-based model of botulism-associated neurotoxicity involving the light chain of Clostridium botulinum toxin type A showed knockdown...
BC Week In Review | Jan 18, 2016
Clinical News

RT001: Interim Phase II data

Interim data from a double-blind, U.S. Phase II trial in 67 patients with primary axillary hyperhidrosis showed that a single application of high-dose topical RT001 significantly reduced gravimetrically measured sweat production at week 4 vs....
BC Week In Review | Oct 5, 2015
Clinical News

RT001: Phase III started

Revance began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate single doses of topical RT001 applied to both sides of the face in up to 450 patients with moderate to severe lateral canthal lines....
BC Week In Review | May 4, 2015
Clinical News

Evosyal: Completed Phase III enrollment

Strathspey’s Alphaeon subsidiary completed enrollment in a pair of double-blind, placebo-controlled, U.S. Phase III trials evaluating injections of Evolus. The trials were each targeting 324 patients. Alphaeon gained exclusive rights to market Evolus in the...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Clostridium botulinum toxin type A; botulinum neurotoxin type A1 nontoxic-nonhemagglutinin component (ntnH) Structural and in vitro studies suggest inhibiting binding between C. botulinum...
BC Innovations | Mar 8, 2012
Distillery Therapeutics

Indication: Autoimmune Disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease Indoleamine 2, 3-dioxygenase (INDO; IDO) Mouse studies suggest IDO could help treat and prevent autoimmune diseases. In lupus-prone mice, an IDO inhibitor...
BC Week In Review | Oct 10, 2011
Company News

Xoma infectious news

Xoma received a five-year contract worth up to $28 million from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to develop antitoxins to treat Type C and D botulism poisoning. Xoma has received about...
BC Week In Review | May 9, 2011
Clinical News

XOMA 3AB: Phase I started

Xoma said NIH's National Institute of Allergy and Infectious Diseases (NIAID) began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single doses of XOMA 3AB in about 24 healthy volunteers. Xoma Ltd. (NASDAQ:XOMA),...
BC Innovations | Feb 24, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium; ebola; malaria Clostridium botulinum toxin type A In vitro and mouse studies identified 1,7-bis(aminoalkyl)diazachrysene-based derivatives that could help treat...
Items per page:
1 - 9 of 9